# FBIO catalysts: Fortress Biotech, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/fbio/catalysts

> Fortress Biotech, Inc. (FBIO) has 1 upcoming catalyst. The next is the FB-607 topline data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for FBIO?

Fortress Biotech, Inc. (FBIO) has 1 upcoming catalyst. The next is the FB-607 topline data readout, 2H 2027. Press release filed with the SEC (EX-99): "FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027." [Calendar and source filings](https://sec-api.dev/companies/fbio/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-126525, https://www.sec.gov/Archives/edgar/data/1429260/000110465926126525/fbio-ex99d1.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/fbio/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Fortress Biotech, Inc. |
| Ticker | FBIO (Nasdaq) |
| SEC CIK | 1429260 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/fbio |

## Cash runway

Cash $152.2M as of 2026-09-30; quarterly burn $6.2M; about 73.7 months of runway at that rate (XBRL company facts, accession 0001104659-26-126531).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2024 | [UNLOXCYT (cosibelimab) NDA/BLA acceptance](https://sec-api.dev/pdufa/cosibelimab) | FBIO | metastatic or locally advanced cSCC | completed | "In July 2024, the FDA accepted the Biologics License Application ("BLA") resubmission for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation and set a PDUFA goal date of December 28, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm)) |
| Q4 2024 | [Fortress Biotech, Inc. topline data readout](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | scheduled | "Triplex, a vaccine for control of cytomegalovirus ("CMV"), is currently being studied in a Phase 2 clinical trial for adults co-infected with HIV and CMV that is now fully enrolled with topline data anticipated in the fourth quarter of 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015740/fbio-20240930x10q.htm)) |
| November 4, 2024 | [Emrosi (DFD-29) PDUFA date](https://sec-api.dev/pdufa/dfd-29) | FBIO |  | completed, approved | "In March 2024, the FDA accepted the NDA for DFD-29 and set a PDUFA goal date of November 4, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015740/fbio-20240930x10q.htm)) |
| November 14, 2024 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm)) |
| December 13, 2024 | [UNLOXCYT (cosibelimab) FDA approval](https://sec-api.dev/pdufa/cosibelimab) | FBIO | metastatic or locally advanced cutaneous squamous cell carcinoma | completed, approved | "On December 13, 2024, Checkpoint Therapeutics ("Checkpoint"), a majority-controlled subsidiary of Fortress Biotech, Inc. (the "Company" or "Fortress"), announced that the U.S. Food and Drug Administration (the "FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") who are not candidates for curative surgery or curative radiation." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/fbio-20241213x8k.htm)) |
| December 28, 2024 | [UNLOXCYT (cosibelimab) PDUFA date](https://sec-api.dev/pdufa/cosibelimab) | FBIO | metastatic or locally advanced cutaneous squamous cell carcinoma | completed, approved | "We could achieve up to two more U.S. FDA approvals in the next nine months, and our next anticipated PDUFA goal date is December 28, 2024, for cosibelimab, an anti-PD-L1 antibody, for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm)) |
| January 6, 2025 | [ZYCUBO (CUTX-101) NDA/BLA acceptance](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease | completed | "On January 6, 2025, we announced that the FDA accepted the NDA for CUTX-101 for priority review, and on January 16, 2025, we disclosed the extension of the PDUFA target action date to September 30, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1429260/000155837025004160/fbio-20241231x10k.htm)) |
| March 31, 2025 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/fbio-20250331xex99d1.htm)) |
| May 15, 2025 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm)) |
| Q3 2025 | [Fortress Biotech, Inc. topline data readout](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | scheduled | "Triplex, a potential vaccine and immunotherapy for prevention and control of cytomegalovirus ("CMV"), is currently being studied in a Phase 2 clinical trial for adults co-infected with HIV and CMV that is now fully enrolled with topline data anticipated in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm)) |
| August 14, 2025 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm)) |
| September 30, 2025 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease | completed, complete response letter | "FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm)) |
| October 1, 2025 | [ZYCUBO (CUTX-101) complete response letter (CRL)](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease in pediatric patients | completed, complete response letter | "On October 1, 2025, Fortress Biotech, Inc. issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter for CUTX-101 (copper histidinate)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465925095366/fbio-20251001x8k.htm)) |
| November 14, 2025 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114xex99.htm)) |
| November 14, 2025 | [ZYCUBO (CUTX-101) NDA/BLA submission](https://sec-api.dev/pdufa/cutx-101) | FBIO |  | completed | "November 14, 2025, Sentynl notified Cyprium that Sentynl had resubmitted the NDA for CUTX-101 to the FDA." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465925112945/tm2531443d1_8k.htm)) |
| December 15, 2025 | [ZYCUBO (CUTX-101) NDA/BLA acceptance](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease in pediatric patients | completed | "Miami, FL - December 15, 2025 - Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has accepted the resubmission of the New Drug Application ("NDA") for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465925120893/fbio-20251215xex99.htm)) |
| early 2026 | [MB-108 trial start](https://sec-api.dev/pdufa/mb-108) | FBIO | recurrent GBM sponsored | scheduled | "MB-108 has completed a Phase 1 clinical trial in patients with recurrent GBM sponsored by the University of Alabama at Birmingham ("UAB") (ClinicalTrials.gov identifier: NCT03657576) and UAB is planning to initiate a Phase 1b study in early 2026 for the treatment of patients with recurrent malignant glioma (ClinicalTrials.gov identifier: NCT06614855)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465925111989/fbio-20250930x10q.htm)) |
| January 13, 2026 | [ZYCUBO (CUTX-101) FDA approval](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease in pediatric patients | completed, approved | "Miami, FL - January 13, 2026 - Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has approved ZYCUBO® (copper histidinate, formerly known as CUTX-101) for the treatment of Menkes disease in pediatric patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926003121/fbio-20260113xex99d1.htm)) |
| January 14, 2026 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO |  | completed, approved | "In December 2025, we announced the FDA accepted the resubmission of the NDA for CUTX-101 as a Class 1 resubmission with a new PDUFA target action date of January 14, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926061233/fbio-20260331x10q.htm)) |
| March 31, 2026 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO |  | completed, approved | "As of December 31, 2025, although the NDA for CUTX-101 had been resubmitted and assigned a new PDUFA date of January 14, 2026, following the October 2024 Complete Response Letter, significant uncertainty remained regarding whether approval would be obtained, whether a PRV would be issued, and whether a PPS PRV Sale could be executed on a timely basis on agreeable terms prior to the March 31, 2026 mandatory exchange date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926126531/fbio-20260930x10q.htm)) |
| March 31, 2026 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037749/fbio-20260331xex99.htm)) |
| May 14, 2026 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/fbio-20260514xex99.htm)) |
| August 13, 2026 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/fbio-20260813xex99d1.htm)) |
| late 2026 | [Fortress Biotech, Inc. topline data readout](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | scheduled | "Triplex, a potential vaccine and immunotherapy for prevention and control of cytomegalovirus ("CMV"), is currently being studied in a Phase 2 clinical trial for adults co-infected with HIV and CMV that is now fully enrolled with topline data anticipated in late 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926095964/fbio-20260630x10q.htm)) |
| November 13, 2026 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926126525/fbio-ex99d1.htm)) |
| 2H 2027 | [FB-607 topline data readout](https://sec-api.dev/pdufa/fb-607) | FBIO |  | scheduled | "FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926126525/fbio-ex99d1.htm)) |

## Drugs

- [UNLOXCYT (cosibelimab)](https://sec-api.dev/pdufa/cosibelimab): metastatic or locally advanced cutaneous squamous cell carcinoma, metastatic or locally advanced cscc, with metastatic cutaneous squamous cell carcinoma, with metastatic or locally advanced cutaneous squamous cell carcinoma
- [ZYCUBO (CUTX-101)](https://sec-api.dev/pdufa/cutx-101): menkes disease in pediatric patients, menkes disease, menkes disease, fast track designation for classic menkes disease in patients
- [FB-607](https://sec-api.dev/pdufa/fb-607): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/fbio/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FBIO catalysts: Fortress Biotech, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/fbio/catalysts

```bibtex
@misc{secapidev_companies_fbio_catalysts_20261116,
  title        = {FBIO catalysts: Fortress Biotech, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/fbio/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_fbio_catalysts_20261116","title":"FBIO catalysts: Fortress Biotech, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/fbio/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
